ProQR Therapeutics receives EUR4.7M credit from Dutch government for QR-110
ProQR Therapeutics announced that it was awarded an innovation credit by the Dutch government for the clinical development and efforts to obtain marketing approval for the QR-110 program that is being developed for patients with Leber's congenital amaurosis 10, or LCA10, a genetic eye disease that is the leading cause of childhood blindness. Repayment of the credit is triggered only by market approval of QR-110. ProQR was awarded an Innovation credit for the QR-110 program. Amounts will be drawn under this facility from 2018-2021.The credit of EUR4.7M through December 31, 2021 will be used to conduct the Phase 2/3 clinical study and efforts to obtain regulatory and ethical market approval of QR-110 for LCA10.